Top 4 Biosimilar Developments of 2021
December 10th 20212021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA. Take a look at Managed Healthcare Executive's top four biosimilar developments of 2021.
Read More
Biosimilar Growth Impressive But New Policies Needed, AAM Exec Says
October 8th 2021Three pieces of legislation that would provide incentives to prescribers and put generics and biosimilars in favorable formulary tiers would speed further prescribing and use of biosimilars, Christine Simmon told Managed Healthcare Executive.®
Read More
When it Comes to Text Messaging with Patients, How Much is Too Much?
April 2nd 2021Especially during the COVID-19 pandemic, healthcare systems and a variety of other healthcare entities have been sending lots of text messages to patients. Reminders about appointment, prompts to take medications, health information updates — they are part of healthcare’s new enthusiasm for all things digital and remote.
Read More
NORD Report: COVID-19 Telehealth Surge Especially Important for People With Rare Diseases
November 12th 2020Telehealth during the COVID-19 pandemic has been especially important to patients with rare disorders, many of which are autoimmune diseases, according to a recent report from the National Organization for Rare Disorders.
Read More